Coeptis Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COEP research report →
Companycoeptispharma.com
Coeptis Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies.
- CEO
- David Mehalick
- IPO
- 2020
- Employees
- 5
- HQ
- Wexford, PA, US
Price Chart
Valuation
- Market Cap
- $57.63M
- P/E
- -18.40
- P/S
- 40.76
- P/B
- 5.76
- EV/EBITDA
- -4.14
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -196.73%
- Op Margin
- -912.42%
- Net Margin
- -380.22%
- ROE
- -40.58%
- ROIC
- -34.49%
Growth & Income
- Revenue
- $1.36M · 0.00%
- Net Income
- $-11,917,015 · -9.56%
- EPS
- $-2.81 · 50.27%
- Op Income
- $-13,043,498
- FCF YoY
- -29.38%
Performance & Tape
- 52W High
- $21.41
- 52W Low
- $6.80
- 50D MA
- $12.25
- 200D MA
- $13.72
- Beta
- -0.43
- Avg Volume
- 50.88K
Get TickerSpark's AI analysis on COEP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 24, 26 | BSG Series CM, LLC | other | 0 |
| Feb 11, 26 | Cogley Brian | other | 12,500 |
| Feb 11, 26 | Cogley Brian | other | 10,000 |
| Feb 11, 26 | Deschamps Philippe | other | 5,700 |
| Feb 11, 26 | Deschamps Philippe | other | 3,250 |
| Feb 11, 26 | Calise Chris | other | 3,250 |
| Feb 11, 26 | Calise Chris | other | 5,700 |
| Feb 11, 26 | Mehalick David | other | 148,875 |
| Feb 11, 26 | Mehalick David | other | 51,250 |
| Feb 11, 26 | Cochran Christopher P. | other | 5,700 |
Our COEP Coverage
We haven't published any research on COEP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate COEP Report →